Skip to content
Wide Range of Medications Help 24/7: support@mexicanpharmacyking.com
Our Products

Rivaroxaban (Xarelto)

Active ingredient: Rivaroxaban
Indications:

Prevention and treatment of venous thromboembolism and reduction of stroke or systemic embolism risk in appropriately selected patients.

Manufacturer
Market supply varies
Airmail Shipping
No Tracking8–20 days$14.95
Express Shipping
Tracking3–10 days$30.00
Available Options
$1,012.30 MXN$55.99 USD
Ordering process

How It Works

  1. 1Step 01
    Choose a product in the catalog or find it with search.
  2. 2Step 02
    Select the option you need on the product page.
  3. 3Step 03
    Go to Cart and enter your contact and order details.
  4. 4Step 04
    Complete payment using the available payment method.
  5. 5Step 05
    Send a prescription to email after placing the order for medications that require a prescription.

Rivaroxaban (Xarelto) is an oral direct factor Xa inhibitor used to prevent or treat thromboembolic disease in selected patients; it provides fixed-dose anticoagulation without routine INR titration, but indication, dose, kidney and liver function, food requirements, bleeding risk, procedures, and interacting medicines still determine whether a particular regimen is appropriate.

What to Know

  • Xarelto does not use routine INR-based dose adjustment, but anticoagulant regimens are still indication-specific and should not be interchanged by tablet strength alone.
  • For the 20 mg tablet, absolute bioavailability is about 66% when fasting; taking it with food raises mean AUC by about 39% and peak concentration by about 76%.
  • Rivaroxaban reaches maximum plasma concentrations roughly 2–4 hours after a tablet, while its terminal half-life is about 5–9 hours in younger adults and 11–13 hours in older adults.
  • The 15 mg and 20 mg strengths are taken with food under U.S. labeling, whereas the 10 mg strength can be taken with or without food.
  • Premature discontinuation can increase thrombotic risk, while continuing anticoagulation through an invasive procedure can increase bleeding risk; peri-procedural timing has to be planned.

Xarelto — Rivaroxaban Anticoagulation Without Routine INR Titration

Xarelto is the best-known brand of rivaroxaban, a direct factor Xa inhibitor used in several very different anticoagulation settings. It may be prescribed for stroke prevention in nonvalvular atrial fibrillation, treatment of deep-vein thrombosis or pulmonary embolism, prevention of recurrent venous thrombosis, and prophylaxis after certain orthopedic procedures, among other approved uses. Those indications do not share one universal dose, so the condition being treated is part of the prescription, not background information.

The current Xarelto listing contains six options across 10 mg, 15 mg and 20 mg tablets, with prices from $55.99 to $167.99 according to strength and quantity. Those presentations correspond to different anticoagulation regimens, so a lower-strength tablet should not be treated as a substitute for a higher-strength prescription simply because it is available in the same product listing.

Why Factor Xa Inhibition Changes the Monitoring Routine

Rivaroxaban reduces thrombin generation by inhibiting activated factor X. Unlike warfarin, it does not require routine INR testing to adjust each dose. That convenience is significant, but it can be misunderstood. The absence of INR titration does not mean there is nothing to monitor. Kidney function, liver function, adherence, bleeding, planned procedures and interacting medicines all remain relevant, while the correct dose depends on indication and renal function.

Standard clotting tests can also be difficult to interpret in a patient taking rivaroxaban. PT or INR may change, but the result is not calibrated in the same manner as warfarin therapy. When drug activity needs to be assessed urgently, clinicians use the clinical context and, where available, assays designed for factor Xa inhibitors.

Food Requirements at 15 mg and 20 mg

One of the most useful useful distinctions with rivaroxaban is the food requirement. U.S. prescribing information directs patients to take 15 mg and 20 mg doses with food because absorption at those strengths is greater with a meal. The 10 mg dose can be taken with or without food. That difference is easy to overlook if several strengths have been used during the same episode of treatment.

This becomes particularly important during the transition from an initial treatment phase to a maintenance phase. The patient may move from a higher-frequency schedule to a different daily dose, and the meal instructions may change with it. A refill should therefore be checked against the current stage of treatment instead of against an old bottle.

Missing Doses Is Not the Same as Missing a Vitamin

Rivaroxaban has a much shorter pharmacologic persistence than warfarin. Its terminal half-life is roughly 5–9 hours in younger adults and about 11–13 hours in older adults. Anticoagulant effect therefore falls substantially when doses are missed. At the same time, taking extra tablets to “catch up” can increase bleeding risk. Missed-dose advice differs by regimen, especially when rivaroxaban is temporarily prescribed twice daily during acute venous-thromboembolism treatment.

The safest response is to use the instructions for the exact regimen. A patient who repeatedly forgets doses should tell the prescriber, because an anticoagulant only provides reliable protection when it is actually taken on schedule.

Bleeding Risk Has to Be Considered Before Procedures

Dental work, endoscopy, surgery, spinal procedures and injections can create questions about interruption. Stopping too early can expose a patient to stroke or recurrent thrombosis; continuing too close to a high-bleeding-risk procedure can create the opposite problem. There is no responsible universal instruction to “stop Xarelto for a few days.” Timing depends on the procedure, kidney function, dose and thrombotic risk.

Patients should tell every clinician involved that rivaroxaban is being taken, including dentists and emergency departments. Spinal or epidural procedures deserve particular attention because bleeding around the spinal cord can cause neurologic injury. New back pain with leg weakness, numbness or bladder or bowel dysfunction after such a procedure requires urgent assessment.

Which Symptoms Need More Than Routine Follow-Up?

Black or tarry stools, vomiting blood, coughing blood or persistent visible blood in urine. A severe or unusual headache, especially after a fall or head injury. New weakness, fainting, shortness of breath or marked pallor that could indicate significant blood loss. Bleeding that does not stop with reasonable local pressure. Sudden leg swelling, chest pain or neurologic symptoms after an interruption, which may indicate thrombosis instead of bleeding.

Minor bruising or a small amount of bleeding can occur, but the location, persistence and clinical context determine how concerning it is. The important mistake to avoid is assuming that all bleeding is expected simply because the medicine is an anticoagulant.

Kidney Function Can Change the Dose

Rivaroxaban is partly eliminated through the kidneys, and renal impairment can increase exposure. Dosing thresholds differ across indications, which is another reason a dose cannot be judged without knowing what it is treating. Acute illness, dehydration or progression of chronic kidney disease can make an old prescription worth rechecking even when the patient has used Xarelto for years.

Liver disease can also be important because rivaroxaban should be avoided in certain patients with moderate or severe hepatic impairment or liver disease associated with coagulopathy. A medication that appears easy because no INR appointment is required still depends on organ function.

Interactions Often Come From P-gp and CYP3A4

Rivaroxaban is a substrate of P-glycoprotein and CYP3A4. Medicines that strongly affect both pathways can materially change rivaroxaban concentrations. Some azole antifungals, HIV protease inhibitors, anticonvulsants and other drugs can therefore create clinically important interactions. NSAIDs and antiplatelet agents may raise bleeding risk through a different mechanism even when they do not greatly change rivaroxaban concentration.

The medication review should include occasional drugs, not only chronic prescriptions. A patient may take ibuprofen for several days, receive an antibiotic or antifungal, or start a supplement without thinking of it as part of the anticoagulation plan. For Xarelto, those additions can be more important than they initially appear.

Xarelto and Eliquis Are Not Milligram-for-Milligram Alternatives

Both rivaroxaban and apixaban inhibit factor Xa, yet their dosing schedules, renal considerations, food instructions and evidence base differ. Rivaroxaban is commonly given once daily in some long-term indications, while apixaban is generally twice daily. The milligram values are also entirely different. A person should never convert between them by comparing tablet strength or price.

Switching anticoagulants requires coordinated timing so that there is neither a gap in protection nor excessive overlap. That transition should come from a prescriber or anticoagulation service, not from availability of a particular package.

How the Catalog Options Should Be Used

Once the prescription has been established, select the exact Xarelto strength first and then the required quantity. This is especially important with rivaroxaban because treatment phase and indication can change the dose, and the 15 mg and 20 mg strengths also carry a food instruction that does not apply in the same form to the 10 mg tablet.

Price is relevant for long-term anticoagulation because adherence can be affected by cost, but the lowest-priced strength is not a therapeutic substitute. A 10 mg package has a different clinical role from a 20 mg package, and the food requirement also changes. Matching the prescription comes first.

Why Abrupt Discontinuation Has Its Own Warning

Xarelto boxed warning: “Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events.”

Stopping an anticoagulant before the underlying thrombotic risk has passed can increase the chance of stroke or another clot. This is especially important in atrial fibrillation, where a patient may feel entirely normal and conclude that the medicine is no longer doing anything. The benefit is preventive, so there may be no daily symptom proving that it works.

If bleeding, cost, surgery or another issue makes interruption necessary, the solution is a planned change instead of an unstructured stop. Depending on the reason, the clinician may change timing, choose another anticoagulant or arrange temporary coverage. The correct action depends on why rivaroxaban was prescribed in the first place.

Reversal Exists, but Prevention of Bleeding Is Still Better

Andexanet alfa is a specific reversal agent used in certain life-threatening or uncontrolled bleeding situations involving factor Xa inhibitors, and clinicians may use other hemostatic strategies depending on availability and circumstances. The existence of reversal does not make major bleeding routine or harmless. Emergency teams still need to know the last dose, kidney function, other antithrombotic medicines and the site of bleeding.

Patients should carry an up-to-date medication list or anticoagulant card. In an emergency, knowing that rivaroxaban was taken recently can change imaging, procedure timing and reversal decisions before the patient is able to explain the history.

Once-Daily Dosing Can Be Convenient Without Being Forgiving

For regimens that use once-daily rivaroxaban, convenience can improve adherence, yet the consequence of a missed dose may be more concentrated because a full dosing interval passes before the next scheduled tablet. A stable routine around the evening meal can help when the prescribed 15 mg or 20 mg dose requires food.

Refill planning is part of adherence. Anticoagulation should not be interrupted because an order was placed after the final tablet was already taken.